MedPath

Drug-coating Balloon Treatment in Coronary Artery Disease

Recruiting
Conditions
Coronary Artery Disease
Interventions
Device: DCB treatment
Registration Number
NCT04255563
Lead Sponsor
Nanjing First Hospital, Nanjing Medical University
Brief Summary

Drug-coated balloon (DCB) is an alternative choice for patients with coronary artery disease (CAD). This study is to investigate the efficacy and safety of DCB treatment in patients with CAD.

Detailed Description

This is a prospective, multi-center, registry to enroll patients undergoing DCB treatment.

All subjects undergoing DCB treatment will be enrolled in this study without strict inclusion and exclusion criteria. Data and images will be collected during the index procedure, and at the clinical and angiographic follow-up.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
3000
Inclusion Criteria
  • Patients suitable for DCB treatment
Exclusion Criteria
  • Pregnancy
  • Contraindications to contrast media, antiplatelet therapy, or paclitaxel
  • Expected life less than 12 months
  • Cardiac shock

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
DCB treatmentDCB treatmentDCB (Sequent® Please) treatment will be performed for suitable patients with CAD.
Primary Outcome Measures
NameTimeMethod
target vessel failure (TVF) at 12 months12 months

TVF is defined as the composite of cardiac death, target-vessel myocardial infarction and ischemia-driven target- vessel revascularization.

Secondary Outcome Measures
NameTimeMethod
Bleeding at 12 months12 months

bleeding

Parameter by quantitative coronary angiography at 7 months7 months

Late lumen loss

Bailout drug-eluting stents (DES) implantation rateDuring procedure

Bailout DES implantation rate during procedure by angiographic criteria

Trial Locations

Locations (1)

Nanjing First Hospital

🇨🇳

Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath